Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X

Next Previous
Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efmitermant alfa (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acceleron Pharma

    • Most Recent Events

    • 11 May 2022 Results published in the Neurology
    • 01 May 2020 Results evaluating the effects of ACE-083 injected into the tibialis anterior (TA) muscles of subjects with CMT1 or CMTX and mild-moderate ankle dorsiflexion weakness presented at the 72nd Annual Meeting of the American Academy of Neurology
    • 09 Mar 2020 According to an Acceleron Pharma media release, Acceleron plans to present results of this study at the American Academy of Neurology Annual Meeting in April
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top